CD4 Count And Risk Of Infection In Patients With Brain Tumors
- Determine the frequency and severity of decreases in CD4 counts as a function of
therapy in patients with newly diagnosed malignant astrocytoma.
- Determine whether the decrease in CD4 counts is a significant predictor of infections
or adverse outcomes in these patients.
OUTLINE: This is a multicenter study.
Patients undergo monthly collection of blood for serial CD4 counts and heme-8 with
differential for 1 year for quantitative analysis. Patients also complete a monthly
questionnaire about infections and antibiotic use.
Patients are followed every 2 months.
PROJECTED ACCRUAL: A total of 125 patients (100 with high-grade disease and 25 with
low-grade disease) will be accrued for this study.
Observational Model: Case Control, Time Perspective: Prospective
Frequency and severity of decreases in CD4 counts
Stuart A. Grossman, MD
Sidney Kimmel Comprehensive Cancer Center
United States: Federal Government